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Abstract 
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Reports of canine ependymoma are generally restricted to single case reports with 
tumor incidence estimated at 2-3% of primary central nervous system (CNS) tumors. 
While most commonly reported in the lateral ventricle, tumors can occur anywhere in 
the ventricular system and in extraventricular locations. Rosettes and 
pseudorosettes are a common histologic feature; however, these features can be 
mimicked by other CNS neoplasms. Thirty-seven potential ependymoma cases were 
identified in a retrospective database search of eight institutions, and a histologic 
review of all cases was conducted. Of thirty-seven cases, twenty-two candidate 
cases were further subjected to a consensus histologic and immunohistochemical 
review, and only 5/37 (13.5%) were conclusively identified as ependymoma. The 
neuroanatomic locations included lateral ventricle (3/5), third ventricle (1/5), and 
mesencephalic aqueduct (1/5). Subtypes included papillary (4/5) and tanycytic (1/5). 
Histologic features included rosettes (5/5), pseudorosettes (5/5), ependymal canals 
(2/5), tanycytic differentiation (1/5), blepharoplasts (1/5), ciliated cells (1/5), and high 
nuclear to cytoplasmic ratio (5/5). Immunolabeling for GFAP (4/4) and CKAE1/3 (3/4) 
was found in pseudorosettes, rosettes, and scattered individual neoplastic cells. 
Diffuse, but variably intense cytoplasmic S100 immunolabeling was detected in 3/4 
cases. Olig2 intranuclear immunolabeling was observed in less than 1% of the 
neoplastic cells (3/3). Tumors that had pseudorosettes and mimicked ependymoma 
included oligodendroglioma, choroid plexus tumor, pituitary corticotroph adenoma, 
papillary meningioma, and suprasellar germ cell tumor. These findings indicate that 
canine ependymoma is an extremely rare neoplasm with histomorphologic features 
that overlap with other primary CNS neoplasms.   
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Introduction 
 Ependymal cells are specialized ciliated epithelial cells that line the ventricular 
system. These cells are present throughout the central nervous system and perform 
a number of functions, including interaction with the subventricular zone during 
development and regulation of permeability to cerebrospinal fluid components.3 The 
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ependyma consists of a single layer of cuboidal, ciliated cells that line the ventricles 
and a smaller population of specialized cells called tanycytes, which are most 
commonly located in the third ventricle and have long processes that interact with 
the adjacent neuroparenchyma.3 In veterinary species, neoplasms with ependymal 
differentiation (ependymomas) are uncommon to rare with the incidence highest in 
cats.18 In dogs, the incidence of ependymoma is difficult to determine due to limited 
scientific literature; however, one retrospective series reported only one case of 
ependymoma in 435 cases of intracranial neoplasia.12 Other reports suggest an 
incidence of approximately 2-3% of all primary intracranial tumors in the dog.15 
Canine ependymoma is reported most frequently in the lateral and third ventricles 
and rarely in the spinal cord.15 Regardless of location, tumors typically manifest 
grossly as a large, intraventricular mass that variably infiltrates and compresses the 
adjacent parenchyma.9,14,15,17,19 Histologically, their appearance can be quite diverse, 
and subtypes include clear cell, papillary, and tanycytic.9,14,15,17 Diagnosis is aided by 
the presence of perivascular pseudorosettes with anti-basilar nuclei and cytoplasmic 
processes that abut blood vessels; however, this pattern is not unique to 
ependymomas and can be easily misinterpreted. Immunohistochemistry and 
transmission electron microscopy can aid in the diagnosis, the latter used to confirm 
the presence of desmosomes and cilia. Herein, we describe a case series of canine 
ependymomas that was derived from a multi-board certified veterinary pathologist 
consensus review of cases previously diagnosed as ependymoma at respective 
institutions. Given the challenges in accurately diagnosing ependymoma based 
solely on histology, we briefly review the neoplasms that were misdiagnosed as 
ependymoma and provide diagnostic support for the alternate microscopic 
interpretations.   
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Materials and Methods 
 Biopsy and necropsy records for the New York State Animal Health 
Diagnostic Center, Cornell University College of Veterinary Medicine (1979-2015), 
University of Georgia Department of Pathology and Athens Veterinary Diagnostic 
Laboratory (2000-2015), Auburn University College of Veterinary Medicine, 
Department of Pathobiology (1996-2016), The Animal Medical Center, Department 
of Anatomic Pathology (1999-2015), Animal Health Trust (1990-2015), Texas A&M 
University College of Veterinary Medicine & Biomedical Sciences, Department of 
Veterinary Pathobiology (2002-2015), and The Royal Veterinary College, 
Department of Pathobiology and Population Sciences (1997-2017) were searched 
for cases of canine ependymoma. Additional select cases were provided from the 
Armed Forces Institute of Pathology archives by one co-author (YS). All cases that fit 
inclusion criteria (i.e. coded in the respective institutional computer system as 
ependymoma) were reviewed by all co-authors, and from this initial review, cases 
that were clearly not ependymoma based on inconsistent histologic features were 
removed from consideration. Consensus was based on at least 75% agreement 
amongst the reviewers. The following immunohistochemical stains were used: glial 
fibrillary acidic protein (GFAP; rabbit polyclonal, Agilent, Carpinteria, CA, catalog 
#Z0334), cytokeratin AE1/AE3 (CKAE1/3; mouse monoclonal, Agilent, catalog 
#MS351501-2), oligodendrocyte transcription factor 2 (Olig2; rabbit monoclonal, 
Abcam, Cambridge, MA, catalog #AB109186), S100 (rabbit polyclonal, Agilent, 
catalog #IS50430-2), and adrenocorticotropic hormone (ACTH; mouse monoclonal, 
Agilent, catalog #M350101-2). The stains were reviewed by the co-authors before 
coming to a consensus diagnosis. PTAH histochemical staining and ACTH 
immunohistochemistry were only performed on select cases based on the histologic 
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features, whereas GFAP, CKAE1/AE3, Olig2, and S100 were performed on all cases 
in which tissue was available. 
 PTAH staining was performed according to standard laboratory protocols. The 
following protocols were used for immunohistochemistry utilizing the Leica Bond Max 
Automated Immunohistochemistry Staining System, according to the manufacturer’s 
instructions (Leica Microsystems, Illinois, United States). Briefly, tissues were 
sectioned at 5 μm and deparaffinized with Bond Dewax Solution (Leica, catalog 
#AR9222). Pretreatment with heat-induced antigen retrieval was performed for 30 
minutes using Tris/EDTA pH 9 (Bond Epitope Retrieval Solution 2, Leica, catalog 
#AR9640) for CKAE1/3 and Olig2. No pretreatment was used for GFAP, S100, and 
ACTH. Endogenous peroxidase activity was blocked with a 3% peroxide solution for 
5 minutes (Leica, catalog #DS9800). The antibodies were diluted at 1:500 for 15 
minutes (GFAP), 1:200 for 60 minutes (CKAE1/3 and Olig2), 1:400 for 14 minutes 
(S100), and 1:200 for 30 minutes (ACTH). Biotin-free PowerVision poly-polymeric 
horseradish peroxidase anti-mouse (Leica, catalog #PV6114) or anti-rabbit (Leica, 
catalog #PV6119) IgG reagent was then applied to the slides for 30 minutes followed 
by incubation with Bond Polymer Refine Detection for 10 minutes (Leica, catalog 
#DS9800). Tissues were developed with 3,3-diaminobenzidine (DAB) (Leica, catalog 
#DS9800) for 10 minutes. The slides were counterstained with hematoxylin (Leica, 
catalog #DS9800) for 5 minutes, dehydrated, cleared, and mounted. Positive 
controls consisted of normal canine brain (GFAP, Olig2, and S100), small intestine 
(CKAE1/3), and pituitary gland (ACTH). Negative controls consisted of an isotype-
matched antibody. 
Results 
7 
 
Thirty-seven cases were originally identified by computer search and after 
initial histologic review, twenty-two cases (60%) had histologic features potentially 
consistent with ependymoma and therefore were included for further analysis. Of the 
fifteen cases that were not subject to further review, diagnoses included 
oligodendroglioma (6/15), pituitary adenoma (3/15), astrocytoma (3/15), 
nephroblastoma (1/15), meningioma (1/15), and non-diagnostic (1/15). Of the 
twenty-two cases reviewed for consensus diagnosis, only 5/22 (22.7%) were 
diagnosed as ependymoma based on the combination of histologic, histochemical, 
and immunohistochemical features. Breed, sex, age, tumor location, and tumor 
subtype are described in Table 1. Four of the cases were classified as papillary 
ependymomas and one as a tanycytic ependymoma. Papillary ependymomas were 
characterized by cords, ribbons, and papilliform projections of neoplastic ependymal 
cells that had moderate amounts of cytoplasm and round to ovoid nuclei with a 
dense chromatin pattern (Fig. 1). All ependymomas had rosettes (5/5) and 
pseudorosettes (5/5) (Figs. 2-3). Rosettes often contained intraluminal, pale 
basophilic material (Fig. 3). The single case of ependymoma with tanycytic 
differentiation had elongated cells with flattened, spindled nuclei (Fig. 4). Fewer 
cases had ependymal canals (2/5), blepharoplasts (1/5), and ciliated cells (1/5) (Fig. 
5). One case had clear progression from a thickened, dysplastic ependyma (Fig. 6).  
A high nuclear to cytoplasmic ratio (5/5) and areas of necrosis (3/5) were features in 
a majority of cases. Hemorrhage, microvascular proliferation, and areas of 
calcification were absent in all cases. Atypia was moderate in all cases and the 
mitotic rate was less than one per 400x field (2.37 mm2) in all cases. Multifocal 
cytoplasmic staining for PTAH was present in the one case in which this stain was 
used. Strong cytoplasmic immunolabeling for GFAP (4/4) was found in 
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pseudorosettes (Fig. 7), rosettes, and in up to 60% of the neoplastic cells not forming 
pseudorosettes or rosettes (Fig. 8). Strong cytoplasmic immunolabeling to CKAE1/3 
(3/4) generally mirrored the GFAP staining and was found in pseudorosettes, 
rosettes (Fig. 9), and scattered individual neoplastic cells (Fig. 10).  The staining 
intensity for CKAE1/3 was greater in the rosettes than the GFAP immunolabeling. 
Olig2 intranuclear immunolabeling was seen in less than 1% of the neoplastic cells 
(3/3) (Fig. 11). Diffuse, but variable, cytoplasmic S100 immunolabeling was detected 
in 3/4 cases (Fig. 12).   
 Of the remaining potential 17 cases, the following diagnoses were made with 
the addition of immunohistochemical stains coupled with the histologic features: 
oligodendroglioma (6/17), choroid plexus tumor (5/17), pituitary corticotroph 
adenoma (4/17), meningioma (1/17) and suprasellar germ cell tumor (1/17). All 
cases of oligodendroglioma were either primary intraventricular neoplasms or arose 
periventricularly and extended into the ventricular system.  Oligodendrogliomas were 
characterized by sheets of round to ovoid neoplastic cells with a variable amount of 
cytoplasm, round, sometimes molded, nuclei, and a variable chromatin pattern. All 
cases had a significant number of pseudorosettes (Fig. 13), and diffuse intranuclear 
Olig2 immunolabeling was present in nearly 100% of the neoplastic cells (Fig. 13, 
inset). Neoplastic oligodendrocytes lacked immunolabeling for GFAP and CKAE1/3 
and had variable cytoplasmic immunolabeling for S100.  
 All cases diagnosed as choroid plexus tumors were primary intraventricular 
masses composed of dense cords, interlacing tubular structures, and 
pseudorosettes of neoplastic epithelial cells (Fig. 14). Typical papillary and villiform 
projections common in most canine choroid plexus tumors were lacking in many of 
these tumors. CKAE1/3 was diffusely positive in all neoplastic cells of the choroid 
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plexus tumors with strong intracytoplasmic immunolabeling (Fig. 14, inset). Choroid 
plexus tumors lacked immunolabeling for GFAP, Olig2, and S100.  
 The pituitary tumors were entirely restricted to the third ventricle, bulging into 
and compressing the thalamus. These tumors were composed of tubules, rosettes, 
pseudorosettes, and loose clusters of neuroendocrine-like epithelial cells (Fig. 15). 
All cases had rosettes containing basophilic material, mimicking the pattern seen in 
some ependymomas; however, no ciliated cells were present. All cases had robust 
and diffuse intracytoplasmic immunolabeling for ACTH (Fig. 15, inset). CKAE1/3 
immunolabeling in the pituitary tumors was robust and nearly diffuse, and patchy to 
diffuse cytoplasmic S100 immunolabeling was present. Pituitary tumors lacked 
immunolabeling for GFAP and Olig2.  
 For the meningioma case, characteristic meningothelial whorls were present; 
however, a majority of the neoplasm was composed of prominent pseudorosettes of 
meningothelial cells typical for the papillary subtype of meningioma (Fig. 16). Lastly, 
the germinoma case consisted of a multiphasic neoplasm composed of germ-like 
cells admixed with a neuroparenchyma-like stroma. While rare pseudorosettes were 
noted in the germinoma, the histology was distinct from that seen in ependymomas. 
Immunohistochemistry was not deemed necessary to diagnose the meningioma or 
germinoma case.   
Discussion 
Ependymomas are an uncommon to rare glioma in the dog that are most 
frequently reported in the lateral and third ventricles.15 While the cell of origin in the 
dog is not known, studies of human ependymoma reveal features of radial glia, a 
neural stem cell that resides in the subventricular zone.4 Ependymomas are typically 
well-circumscribed intraventricular neoplasms that do not extend extensively into the 
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adjacent parenchyma. Pseudorosettes and rosettes are an important histologic 
feature of these tumors; however, they are not specific to ependymomas and utilizing 
them as the sole criterion for ependymoma diagnosis is ill advised, supported by the 
findings in this study. Important histologic features that are specific to ependymomas 
include ependymal canals (linear spaces lined by neoplastic ependymal cells), 
ciliated epithelial cells lining the rosettes, and blepharoplasts (basal ciliary bodies 
identified by PTAH histochemical staining).7 As demonstrated here, the diagnosis 
can be greatly aided by immunohistochemistry, which typically relies on GFAP 
immunolabeling in pseudorosettes and other parts of the tumor, multifocal pan-
cytokeratin immunolabeling in pseudorosettes, rosettes, and other tumor cells, and 
sparse Olig2 immunolabeling. Human ependymomas commonly express vimentin 
and S100 and rarely express neuronal antigens.5,16 While the underlying molecular 
abnormalities associated with ependymoma in humans are well described and 
include mutational activation of MAPK, PDGFR, and VEGF, the rarity of these 
tumors in the dog has limited molecular characterization.1,13 
 The current case series details the collective efforts and consensus review of 
eight board-certified veterinary pathologists, all of whom have extensive experience 
and expertise with diagnostic veterinary neuropathology. Of the thirty-seven cases 
originally selected from archival searches, only five were confirmed as ependymoma 
based on histology with or without immunohistochemical features. Based on the 
small number of cases, no breed or sex predilection can be determined, and the 
tumors were most common in middle-aged dogs. Three cases involved the lateral 
ventricle, consistent with the predilection sites recorded in the literature. While 
pseudorosettes and rosettes were present in all cases, other more specific features 
of ependymoma (ependymal canals, ciliated cells, and blepharoplasts) were present 
11 
 
in a minority of cases. Four of the cases were diagnosed as papillary ependymomas, 
whereas one had tanycytic features. Most reported cases of canine ependymoma 
are papillary subtypes, with rare reports of clear cell and anaplastic variants.9,14,17,19   
 The inclusion of immunohistochemistry can greatly aid in the diagnosis of 
ependymoma; however, it must be interpreted in context with the expected staining 
patterns of other intracranial neoplasms in the dog. In the current cases series, 
GFAP was immunoreactive in all of the ependymoma cases in which tissue was 
available. Immunolabeling was strong in the cells forming the pseudorosettes and 
rosettes, as well as in single to small clusters of neoplastic cells throughout the 
neoplasm. While GFAP is traditionally used to label cells of astrocytic origin, it is also 
normally expressed in ependyma and radial glial cells, making GFAP expression 
useful in the diagnosis of ependymoma.6,19 In these canine ependymomas, GFAP 
was robustly expressed in pseudorosettes and to a lesser degree in rosettes. A 
similar pattern of immunolabeling was noted for pan-cytokeratin, although 
immunolabeling was often more robust in the rosettes compared to GFAP. 
Cytokeratin expression occurs in the vast majority of ependymomas, but it can be 
widely variable in intensity, ranging from scant immunolabeling to marked 
immunolabeling noted in the pseudorosettes and rosettes.16,18 Importantly, Olig2 
immunolabeling was extremely limited. This is consistent with the staining pattern of 
Olig2 in human ependymomas, in which a minor subset of neoplastic cells has 
expression of Olig2. 4,5 Since this pattern of Olig2 expression is expected with radial 
glia, it is often used to support the contention that these tumors arise from a 
subpopulation of radial glia stem cells.4,5 S100 immunolabeling was present in 3/4 of 
the cases, and while certainly not specific to ependymoma, the multifocal, intense 
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cytoplasmic staining pattern was consistent with that reported in human 
ependymoma.16   
 The presence of pseudorosettes and rosettes can lead to a diagnostic 
dilemma, as these are features that can be recapitulated in a number of primary 
intracranial neoplasms in the dog. In the current consensus series, previously 
diagnosed ependymomas were reclassified as oligodendroglioma, choroid plexus 
tumor, pituitary adenoma, meningioma, and suprasellar germinoma.  
In the dog, gliomas are the second most common primary intracranial tumor, 
with oligodendrogliomas having an incidence of up to 70%.8 Oligodendrogliomas 
have relatively uniform cellularity and are composed of round to polygonal cells with 
round to ovoid nuclei, finely stippled chromatin, and inapparent nucleoli. The 
presence of pseudorosettes can be sporadic or abundant in these tumors and can 
lead to diagnostic confusion when the tumor is located within a ventricle.8,11 
Oligodendrogliomas can have extensive ventricular involvement; however, to 
differentiate ependymoma from oligodendroglioma, several features can be used. 
The presence of the characteristic “fried-egg” autolytic histologic pattern, the 
“chicken wire” vascular pattern, myxoid stroma, nuclear rowing or molding, and 
coarse nuclear chromatin can be used to help distinguish oligodendrogliomas from 
ependymomas. Importantly, Olig2 immunolabeling is typically present in the majority 
of neoplastic cells in oligodendrogliomas, in contrast to the pattern observed in 
ependymomas.8 
 Choroid plexus tumors represent approximately 10% of primary intracranial 
tumors in the dog.15 They arise from the choroid plexus epithelium, occurring 
predominately in the lateral ventricles and fourth ventricles with occasional spread to 
other regions of the ventricular system. Most canine choroid plexus tumors are 
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formed by papillary projections of choroid plexus epithelium supported by a fine 
fibrovascular stroma, but other patterns include tubular-like differentiation, acinar-like 
structures, and sheet-like growth of cuboidal epithelial cells. The small acinar-like 
structures have a central fibrovascular core and mimic a pseudorosette. Unlike 
ependymomas, these tumors are diffusely immunolabeled with pan-cytokeratin and 
lack immunolabeling for Olig2 and GFAP.  Other more specific antibodies to the 
choroid plexus, including Kir7.1, E-cadherin, and N-cadherin, can be used to further 
justify the diagnosis of choroid plexus tumors in the dog.2,10   
 Pituitary gland tumors can invade dorsally to involve the third ventricle and the 
surrounding brain parenchyma. Corticotroph tumors are relatively common in the 
dog and can either be functional or non-functional. Pituitary tumors that include 
rosettes and pseudorosettes can easily be confused with ependymomas, but while 
the histologic pattern may be similar in some respects, the immunohistochemical 
staining patterns are vastly different. Pituitary tumors have abundant immunolabeling 
for pan-cytokeratin and ACTH and are not expected to have immunolabeling for 
GFAP and Olig2.   
Meningiomas, due to their neuroectodermal lineage, can produce a wide 
variety of histologic patterns, but meningothelial whorls are a defining feature, even 
when rarely present within the neoplasm. In addition, the nuclei of meningiomas are 
large with an open chromatin pattern, which is distinct from other primary intracranial 
neoplasms. The papillary subtype of meningioma is the most problematic, as it 
presents with abundant pseudorosettes that can mimic those seen in ependymomas.  
However, the location of the tumor (extra-axial), as well as the presence of 
meningothelial whorls, aids in the diagnosis. There are no immunohistochemical 
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stains that are definitive for canine meningioma, but meningiomas lack 
immunolabeling for Olig2 and can have patchy immunolabeling for pan-cytokeratin.6  
Lastly, germinomas arising in the suprasellar region can invade the third 
ventricle and mimic ependymoma. These tumors have a distinct histomorphology 
composed of clusters, sheets, and islands of germ cells, often with epithelial and 
hepatocyte-like differentiation. Suprasellar germ cell tumors strongly express alpha-
fetoprotein; however, complete immunohistochemical studies of these tumors have 
not been performed in the dog. 
 In conclusion, ependymomas are rare tumors in the dog. While 
pseudorosettes and rosettes are characteristic features of ependymomas, they are 
not pathognomonic. The tumor location (intraventricular), other histologic features 
(ependymal canals, ciliated epithelial cells lining the rosettes, and blepharoplasts), 
histochemical stains (PTAH), and immunohistochemistry (GFAP, pan-cytokeratin, 
Olig2) can help differentiate ependymomas from other primary brain tumors. 
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Figure legends 
Figures 1-6. Brain, canine ependymoma, hematoxylin and eosin (HE). Figure 1. 
Case 1. Rosettes (arrow) and pseudorosettes (asterisk) are common. Figure 2. 
Case 2. Elongate ribbons of neoplastic ependymal cells lining open spaces 
consistent with ependymal canals (arrows). Figure 3. Case 4. Rosettes either have 
empty lumina or contain basophilic material (arrow). Figure 4. Case 2. Elongated 
neoplastic cells consistent with tanycytic differentiation forming pseudorosettes. 
Figure 5. Case 4. Rare rosettes are lined by ciliated ependymal cells. Figure 6. 
Case 5. Neoplastic cells emerge from a thickened, dysplastic ependymal lining.  
Lateral ventricle lumen denoted by asterisk. 
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Figure 7-12. Brain, canine ependymoma, immunohistochemistry (IHC). Figure 7.  
Case 1. GFAP immunolabeling is consistently localized to the processes of 
neoplastic cells that abut blood vessels (pseudorosettes). Figure 8. Case 2. 
Neoplastic cells have strong cytoplasmic immunolabeling for GFAP. Figure 9. Case 
4. CKAE1/3 immunolabeling is intense in rosettes and pseudorosettes. Figure 10. 
Case 2. Diffuse, but variably intense immunolabeling to CKAE1/3. Figure 11. Case 
4. Intranuclear Olig2 immunolabeling is restricted to a small minority of cells 
(arrows). Figure 12. Case 2. Cytoplasmic S100 immunolabeling is strong and 
diffuse.   
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Figure 13-16. Brain, canine, mimics of canine ependymoma. Figure 13. 
Intraventricular oligodendroglioma composed of sheets, cords, and pseudorosettes 
(arrow). Hematoxylin and eosin (HE). Inset: Neoplastic cells have strong, 
intranuclear immunolabeling to Olig2. Immunohistochemistry (IHC.) Figure 14. 
Intraventricular choroid plexus tumor forming cords, tubular-like structures, and 
pseudorosettes. HE. Inset: Neoplastic cells have diffuse, uniform, strong 
intracytoplasmic immunolabeling to CKAE1/3. IHC. Figure 15. Pituitary corticotroph 
adenoma associated with the third ventricle forming rosettes, pseudorosettes, and 
small clusters of neoplastic cells. H&E. Inset: Strong and diffuse cytoplasmic 
immunolabeling to ACTH. IHC. Figure 16. Meningioma forming numerous 
pseudorosettes and rare meningothelial whorls (arrow). HE.  
 
 
Table 1:  Signalment, tumor location, subtype, and immunohistochemical staining profile of cases diagnosed as 
ependymoma. 
 
 
Case 
Number 
Breed Sex Age 
(years)  
Location and 
Subtype 
GFAP Olig2 CKAE1/3 S100 
1 Pekinese M 8 Lateral and third 
ventricle; Papillary 
Faint 
positive 
n/a n/a Negative 
2 Mixed MC 3 Lateral ventricle, 
right; Papillary 
Faint 
positive 
Rare 
positive 
Positive Positive 
3 Boxer MI 10 Mesencephalic 
aqueduct; 
Tanycytic 
n/a n/a n/a n/a 
4 Pointer FS 11 Third ventricle; 
Papillary 
Strongly 
positive 
Rare 
positive 
Positive Positive 
5 Mixed U 7 Lateral ventricle; 
Papillary 
Strongly 
positive 
Rare 
positive 
Positive Faint 
positive 
 
Abbreviations: M = male, not otherwise specified; MC = male castrated; MI = male intact; FS= female spayed; U = 
unrecorded. 
 
